Multiple sclerosis (MS) is an inflammatory, neurodegenerative disease of the CNS characterized by both grey and white matter injury. Microglial activation and a reduction in synaptic density are key features of grey matter pathology that can be modeled with experimental autoimmune encephalomyelitis (EAE).
Introduction:
Multiple sclerosis is an immune-mediated disease of the CNS involving damage to both the white and grey matter. Current immunomodulatory therapies for MS are effective at minimizing relapses and white matter lesion burden, but are less effective at preventing progressive neurodegeneration and cognitive deficits (1). Grey matter degeneration is highly correlated with the progressive component of MS and its accompanying physical and cognitive disabilities (2) (3) (4) (5) . Grey matter pathology involves focal demyelinated lesions and widespread atrophy of cortical and subcortical regions. Grey matter lesions are characterized by activated microglia, axon damage, neuron and glial cell loss, and decreased synaptic density (6) (7) (8) .
Interestingly, activated microglia and synapse loss also occur in myelinated areas of normal-appearing grey matter (9, 10) suggesting direct synaptic injury associated with activated microglia may be involved.
Microglia have been shown to prune synapses by phagocytosis during development by a process of complement-mediated opsonization and subsequent phagocytosis (11) (12) (13) (14) . The complement system can be activated by deposition of C1q, which is thought to tag synapses for elimination and triggers the classical complement pathway, or via the alternative and lectin pathways that are independent of C1q. All three initiating pathways converge to cleave C3 to C3a, a soluble chemokine that recruits phagocytic cells, and C3b which is deposited on activating surfaces as an opsonin that facilitates phagocytosis via the microglia-specific complement receptor 3 (CR3) (11, 15) . C3b can also initiate the lytic pathway leading to formation of the membrane attack complex (MAC) that causes cell lysis, but it is the early complement pathway (C1q -C3) that is implicated in synapse pruning by microglia (11, 16, 17) .
While critical for development, complement also appears to be recruited to mediate pathologic synapse loss during aging as well as in diseases including frontotemporal dementia, Alzheimer's disease, viral encephalitis, traumatic brain injury, and schizophrenia (16) (17) (18) (19) (20) (21) (22) . Experiments in mouse models such as the mutant SOD1 model of ALS and a model of HIV associated neurocognitive disorder (HAND) suggest that microglial activation and synapse loss may occur independent of complement in other diseases (23, 24) .
Thus, the goal of this study was to evaluate whether complement-dependent synapse loss contributes to grey matter degeneration and neurocognitive deficits in EAE.
Complement involvement in the white matter pathology of MS is well-established. Complement activation products including the MAC complex are abundant in human white matter lesions (25, 26) .
Evaluation of the role of the terminal lytic pathway in EAE has yielded mixed results (27) (28) (29) (30) (31) (32) . However, the alternative complement pathway plays a major role in driving pathology in EAE. Knockout of C3, Factor B, or receptors to C3 cleavage products (C3aR, CR3, and CR4) all reduce white matter lesion pathology and motor impairment measured by the EAE clinical score (33) (34) (35) (36) (37) (38) .
The role of complement in MS grey matter degeneration has only begun to be addressed. Two recent studies on human postmortem samples indicate that early complement components C1q, C3b-iC3b, C3d (a deactivated cleavage product of C3 that can mark areas of chronic complement activity), and alternative pathway component Bb do accumulate in cortical, hippocampal, and thalamic grey matter of MS patients (9, 39) . Within the hippocampus, C1q and C3d were increased in both myelinated and demyelinated regions of CA1-3 that also displayed synapse loss and microglial activation. C1q and C3d also co-localized with synaptic markers within microglial processes, suggesting that complement-opsonized synapses were potentially phagocytized by microglia (9) . There was no sign of the terminal MAC in the hippocampus (9, 39) , showing that the early complement pathway is the most relevant to progressive MS grey matter pathology. As the early complement pathways are correlated with the synapse reduction observed in MS patients, it is important to determine whether the relationship is causative and thus potentially preventable using animal models.
MOG -induced EAE provides a good animal model of MS grey matter injury. The hippocampi of EAE mice have pronounced microglial activation, synapse loss, and some atrophy of pyramidal cell layers that occurs independently of extensive myelin loss, axon injury, or focal lesions (40) (41) (42) (43) (44) . EAE mice also show impaired synaptic transmission and deficits in hippocampal-dependent behavior (41, 45, 46) indicating that EAE mice have cognitive impairments analogous to progressive MS patients.
We have used the MOG EAE model to test the hypothesis that the EAE inflammatory environment results in excess complement production and activation in the brain to make synapses vulnerable to pruning from phagocytic microglia. Our results show that complement proteins C1q and C3/C3d are elevated in the hippocampus of EAE mice and that genetic deletion of C1q or C3 provides varying levels of protection from EAE-induced synapse loss and microglial activation.
RESULTS:

C1q and C3 expression in EAE hippocampus
Our lab has previously shown that EAE immunization results in significant synapse loss in the CA1statum radiatum of the hippocampus, which is largely spared from demyelination (40, 47) . To determine if this region also exhibits increased complement production and deposition in EAE that could make synapses vulnerable to phagocytosis by glia, we performed IHC using anti-C1q and anti-C3d antibodies (Figure 1 ). C1q protein levels were significantly increased in the hippocampus of EAE mice compared to sham-immunized controls (Figure 1 A-C). By IHC we measured a 1.6-fold increase in mean C1q fluorescence across the hippocampus in EAE vs sham mice (p=0.02; t-test) with significant increases ranging from 1.5-1.9-fold in all sub-regions of the hippocampus (n=17 mice per group; Figure 1 A, C). At high (60-100x) magnification we observed that C1q was diffusely localized throughout the neuropil but also was localized at higher density in small punctate regions, some of which co-localized with synapses or along the dendrites in both sham and The C3d antibody, which detects both full-length C3 and activated/deactivated cleavage products that contain the C3d region reflects both expression and chronic deposition of the active complement pathway.
C3d puncta are found at a low level throughout the hippocampus with the highest density occurring in sham mice within the lacunosum molecular layer. In EAE mice there was an increase in C3d puncta in the CA1stratum radiatum region of the hippocampus compared to sham that is just shy of significant (Figure 1 G; % of CA1-SR area occupied by C3d: EAE: 1.8% vs Sham: 1.2%; p=0.15 t-test). The lacunosum and dentate molecular layers that have higher C3d expression at baseline did not have increased C3d puncta in EAE compared to sham.
We next analyzed expression of complement components in EAE and sham mice by Western blot.
Similar to our IHC results, we found that C1q expression in the hippocampus of EAE mice was increased 2.6fold compared to sham (Figure 2 A; p<0.001; t-test). Expression of full length C3 was also elevated in EAE mice 1.9-fold above sham controls (Figure 2 B; p=0.003; t test). We next analyzed expression of a negative regulator of the complement pathway, namely complement factor H (CFH), and saw that it too was elevated in EAE (1.3-fold above sham; p=0.005; t-test) suggesting that the balance between activation and inhibition was not completely shifted (Figure 2 C) by the increased expression of C1q and C3.
Comparison of EAE pathology in WT, C1qa KO, and C3 KO Mice
Loss of C3 but not C1q results in less severe EAE motor impairment
Next, we immunized wild type (WT), C1qa knockout (KO) and C3 KO mice for EAE to determine whether the early complement pathway is a key driving component of synapse loss within the grey matter in EAE, particularly in the hippocampus. We also assessed whether the loss of C1q or C3 could protect against the EAE-induced motor impairment caused by spinal cord damage ( Figure 3 ). As previously reported (33, 35, 38) , C3 knockout resulted in less severe EAE motor deficits with a significant decrease in the mean clinical score both at peak disease (14-15 days post immunization) and during the chronic phase (20-30 days post immunization). On the other hand, C1qa KO did not alter the EAE disease course in any way as the C1qa KO EAE mean clinical scores were virtually identical to WT EAE. Neither C1qa KO nor C3 KO altered the timing of motor symptom onset. This result is consistent with the conclusion that it is primarily the alternative complement pathway that plays an important role in EAE white matter disease (29) .
C1qa and C3 knockout mice have less EAE-induced synapse loss
As we have previously documented significant synapse elimination (40) and increased expression of C1q and C3d in the CA1-stratum radiatum layer of the hippocampus of EAE mice, we chose to focus on this same region for this study on grey matter synapse loss. Loss of early complement genes C3 and C1qa protected synapses during EAE ( Figure 4 ). WT mice with EAE displayed a 10% decrease in the number of Homer1 puncta in the CA1-striatum radiatum of the hippocampus compared to sham controls (p=0.002; Sidak). C1qa KO mice showed partial protection against EAE-induced synapse elimination as they had only 6% loss in Homer1 synaptic density compared to C1qa KO sham controls, and the synapse loss was no longer statistically significant (p=0.32). C3 KO also were protected against EAE-induced synapse loss with no significant difference between sham and EAE (2.7% decrease; p=0.95). Similar results were found for synaptic density measured via PSD95 puncta. WT EAE mice had a significant, 17% loss of PSD95+ postsynaptic puncta compared to sham controls (p=0.02) whereas C1qa KO EAE mice had 11% fewer and C3 KO EAE mice had 6% fewer PSD95+ synaptic puncta than sham controls of the same genotype. Both C1qKO and C3 KO EAE groups were no longer significantly different from sham controls (C1qKO p=0.39; C3 KO p=0.94).
C1qa KOs with EAE showed a small improvement in synaptic density over WT, suggesting that C1q plays a small role in EAE-induced synapse elimination but is not the primary driver. Knockout of C3 proved to be much more effective at preventing synapse loss. This could suggest that the alternative pathway is more important in grey matter pathology through C3-mediated opsonization and phagocytic removal and/or proinflammatory signaling via C3a. However, the significant improvement in EAE clinical scores in C3 KO mice indicate that loss of C3 provided protection from white matter spinal cord disease and suggest that C3 KO may reduce inflammation elsewhere in the CNS and perhaps systemically. Thus it is difficult in this model system to distinguish between hippocampal protection due to loss of C3 activity directly at the synapses versus secondary to wider reduction in disease severity.
C3 knockout mice, but not C1q knockout mice, have less microglial activation
We next assessed whether C1qa or C3 KO could alter the morphometric parameters of microglial activation induced by EAE in the hippocampus. In WT mice, EAE immunization results in increased IBA1 expression by microglia as well as a change in microglial morphology that results in thicker and shorter processes that has been associated with a reactive microglial phenotype ( Figure 5 ). This change in microglial cell morphology can be measured by a decrease in the surface area/volume ratio and a decrease in the skeletal length/volume ratio of IBA1+ cells. WT EAE mice have a significant 1.24-fold increase in the average IBA1+ cell volume per field of view compared to WT Sham (p=0.03; Sidak) and a significant 1.46-fold increase in the summated IBA1 intensity compared to WT Sham (p=0.003). C1qa KO EAE mice show a similar 1.38fold increase in IBA1+ cell volume and a 1.57-fold increase in IBA1 intensity compared to C1qa KO shams (p=0.003 and p=0.004 respectively). However, C3 KO EAE mice had no increase in IBA1 volume (1.01-fold; p=0.99) and only a small, insignificant increase in IBA intensity (1.14-fold; p=0.94) compared to C3 KO shams.
Similar results were obtained for the surface value/volume ratio and skeletal length/volume ratio. C1qa KO EAE and WT EAE mice had similar significant decreases in these two microglial morphology measurements compared to genotype-matched sham controls (Surface area/volume: WT EAE 0.88, p<0.001; C1qa KO EAE 0.88, p=0.001 compared to 1.0 in genotyped matched sham controls; Skeletal Length/volume: WT EAE 0.77, p<0.001; C1qaKO EAE 0.76, p=0.002; compared to 1.0 in genotyped matched sham controls). C3 KO EAE mice, however, only showed small, insignificant decreases in the surface area/volume ratio (C3 EAE 0.96 vs C3 sham 1; p=0.68) and skeletal length/volume ratio (C3 KO EAE: 0.93 vs C3 sham 1; p=0.89). Taken together, these results show that C3 KO prevented hippocampal microglial activation induced by EAE, but C1qa KO had no effect on microglial morphology in EAE.
C1qa KO does not significantly protect against EAE-induced cognitive impairments.
Finally, we tested whether knockout of C1qa can protect hippocampal-dependent learning and memory specific to contextual fear conditioning. Contextual and cued fear conditioning can be used to assess hippocampal-dependent and -independent memory in mice during the chronic phase of EAE because it is less confounded by EAE motor deficits than learning and memory paradigms that are dependent on mobility and exploratory behavior. Freezing behavior in response to a context or cue stimulus that had been paired with a foot shock during a prior conditioning protocol is measured and distinguished from EAE-associated reductions in baseline mobility by comparison to mobility rates in an unconditioned novel context. We and other groups have reproducibly used fear conditioning to monitor learning and memory in EAE mice (45, 47, 48) .
Our data show that after mice were conditioned with a foot shock and paired auditory cue within a defined contextual environment, WT EAE mice displayed less freezing behavior in the conditioned context compared to a novel context than WT Sham mice (Δ context/control: WT sham = 1; WT EAE = 0.57; p=0.03; Sidak). C1q KO EAE mice had freezing responses were very similar to WT EAE mice (Δ context/control: C1qa KO sham = 1; C1qKO EAE = 0.66; p=0.075; WT EAE vs C1qa KO EAE p=0.82). In response to the conditioned auditory cue, WT EAE showed an insignificant trend towards less freezing than sham controls (WT sham = 1; WT EAE = .83; p=0.34) whereas Sham and EAE C1qaKO mice spent similar time freezing (C1qa KO sham 0.95 vs C1qa KO EAE 0.95; p=0.99). Thus C1qa KO had little overall effect on EAE-induced impairment in hippocampal-dependent contextual fear conditioning.
Discussion
The overall goal of this study was to investigate the contributions of complement proteins to synaptic damage, microglial activation, and neurocognitive deficits in an EAE hippocampal model of MS grey matter pathology. Our results show that mice immunized with MOG Previous studies have shown that genetic ablation of alternative complement pathway components (C3, Factor B) or receptors to C3 cleavage products (C3aR, CR3(CD11b-/-), CR4 (CD11c-/-) protects against EAE spinal cord pathology and associated motor deficits (33, (35) (36) (37) (38) 49) . Additionally, loss of endogenous inhibitors like murine membrane-bound Crry exacerbate the EAE clinical score (50) and treatment with complement inhibitors that limit the C3 convertase, such as CR2-Crry, CR2-CFH, and sCR1, or antibodies that block the alternative pathway have been shown to attenuate the EAE clinical score (29, (51) (52) (53) . On the other hand, components of the classical pathway (C1q, C4) seem largely dispensable for MOG -induced EAE motor impairments with genetic deletions resulting in little to no change in the EAE clinical score, although they may contribute to an auto-antibody exacerbation model of EAE (54, 55) . Our data corroborate this, as C1qa KO had no effect on the EAE clinical score whereas C3 KO mice were partially protected from EAE motor impairments. This is the first study to investigate complement's contribution to synaptic damage within EAE grey matter, where genetic deletion of C1q showed a small level of protection against EAE-induced synapse loss while knockout of C3 provided greater protection. Complement opsonization of synapses followed by microglia phagocytosis is a mechanism for synapse pruning during development and in some disease models including Alzheimer's, frontotemporal dementia, viral encephalitis, aging, traumatic brain injury, and schizophrenia (11, 15-22, 56, 57) . Our results suggest that EAE (and perhaps multiple sclerosis) can be added to this list, although the precise mechanistic roles of C1q and especially C3 need additional studies to elucidate. As C3dependent aspects of the complement pathway contributed not only to decreases in hippocampal synaptic density and microglia activation within the EAE hippocampus but also to motor deficits connected to white matter spinal cord pathology, it is possible that C3 KO may protect grey matter secondarily via systemic reduction in EAE severity in addition to direct effects within the grey matter. Due to the many roles of complement in mediating immune cell functions, the role of C3 in EAE is likely complex. C3 is known to contribute to co-stimulation strength of T-cells and B-cells, chemo-attraction of infiltrating cells, cytokine production, opsonization of myelin and other debris, and likely opsonization of synapses (33, 35, 38, (58) (59) (60) .
Unfortunately, there is no currently available conditional C3 KO mouse to probe the local role of C3 within the hippocampus and it will be important in the future to tease apart the role C3 plays in complement-dependent synaptic pruning from those in white matter inflammation and systemic immune activation in EAE. Regardless though, in light of evidence of complement activation and synaptic phagocytosis reported in grey matter from MS patients (9, 39) , the protective effects of C3 KO on EAE grey matter pathology are exciting given the paucity of treatments for gray matter neuroprotection in MS.
In summary, genetic loss of C1q or C3 provides protection from EAE induced synapse loss within the grey matter and C3 KO additionally protects against microglial activation. This coupled with the protection from EAE motor impairments, in the case of C3 KOs, suggest that the early complement pathway may be an important therapeutic target for MS and may be especially relevant to the grey matter neurodegeneration in progressive MS.
Methods
Animals:
Male and female C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME) at age 7 weeks and were housed for at least 1 week prior to EAE induction. A C3 knockout breeder pair (with C57BL/6 background) was obtained from Jackson (Stock # 029661; (61)). A C1qa knockout (KO) breeder pair was obtained from Dr. Andrea Tenner (University of California, Irvine; (62)). C1q is an oligomeric protein complex originating from 3 genes: C1qa, C1qb, and C1qc. Loss of C1qa prevents correct folding and secretion of the C1q multimer with a complete loss of function (62) . Groupings of male and female mice were used for all reported experiments in relatively equal numbers. Two or three-way ANOVA tests showed no significant main effects of sex or significant interactions of sex with immunization status or genotype so the data was combined and reported from both sexes.
EAE:
We immunized mice with a pre-mixed emulsion (Hooke Labs EK-2110) containing myelin oligodendrocyte glycoprotein peptide, amino acids ) in complete Freund's adjuvant (CFA) containing heat-inactivated mycobacterium tuberculosis H37RA. A 100µl emulsion was injected subcutaneously at each of two sites over the upper and lower back. Sham-immunized sex-matched littermate controls were injected with control emulsion without MOG (Hooke Labs CK-21100), and otherwise received identical treatment. Mice of each genotype were randomly assigned to either the sham or EAE treatment groups. Mice were injected with pertussis toxin (Hooke Labs, 90-400ng intraperitoneally (i.p.), with the dose adjusted according to potency of each lot per manufacturer recommendations for each sex) on 0 and 1 day post-immunization (dpi). In one cohort, WT mice received ~100ul i.p. twice daily of Vehicle solution: 5% DMSO, 40% polyethylene glycol 400, and 55% normal saline beginning on the first day of visible motor deficits (EAE score 0.5 or greater) with timing matched for sham controls. All mice were monitored daily for signs of clinical disease and scored for motor deficits as follows: 0, no deficit; 0.5, partial tail paralysis; 1, complete tail paralysis; 2 hind-limb weakness; 2.5, paralysis of one hind limb; 3, paralysis of both hindlimbs; 3.5, hindlimb paralysis and forelimb weakness; 4; quadriplegia; 5; moribund.
Western blots: At twenty-eight days post-immunization mice were perfused briefly with PBS, hippocampi were isolated, immediately frozen on dry ice, and stored at -80 o C. Hippocampal biopsies were homogenized in RIPA lysis buffer containing a protease inhibitor cocktail (MilliporeSigma: Calbiochem, SetV). The cell lysate was kept on ice with periodic vortexing for 30 minutes then centrifuged at 13,000 rpm for 10 minutes and IHC: At 28-30 days post-immunization, mice were anesthetized with ketamine/xylazine (100 and 10 mg/kg, respectively) and intracardially perfused for 1 minute with phosphate-buffered saline (PBS) containing EDTA (1.5 mg/ml) followed by 4% paraformaldehyde (PFA) in PBS. Brains were post-fixed for 18-24 hours in 4% PFA then stored in PBS at 4°C. Brains were cut into 40μm-thick coronal sections using a vibratome (Leica V1000) and stored in a cryoprotectant mixture of 30% PEG300, 30% glycerol, 20% 0.1 M phosphate buffer, and 20% ddH 2 O at −20°C. We performed free-floating-section IHC. The sections were washed three times for 30 min in PBS to remove the cryoprotectant. Then sections were incubated in 100mM glycine in PBS for 30 minutes followed by citrate antigen unmasking at 37 0 C for 30 minutes (Vector, H3300 with 0.05% tween 20).
Primary antibodies were diluted in blocking buffer consisting of 1.5% BSA (MilliporeSigma; A3294), 3% normal goat serum (Vector Laboratories; NGS; S1000) or 3% normal donkey serum (MilliporeSigma, 566460), 0.5% Triton X-100 (Promega, H5142), and 1.8% NaCl in 1× PBS. We used the following antibodies in these experiments: rabbit anti-Iba1 (Wako Biochemicals, 019-19741; 1:1000) rabbit anti-C1q (Abcam Ab182451 clone 4.8; 1:500), goat anti-C3d (R&D Systems, AF2655, 1:500), chicken anti-Homer1 (Synaptic Systems, 160006, 1:500), and mouse anti-PSD95 (NeuroMab, 75-028, 1:500). Sections were incubated in the primary antibody mixture for 2-3 days at room temperature with agitation. Sections were then washed three times for 30 min in 1× PBS with 1.8% NaCl and then incubated overnight at room temperature in Alexa Fluor-conjugated secondary antibodies (1:500; Invitrogen or 1:250 Jackson Immuno Research) in blocking buffer. Finally, sections were washed 3 times with 1×PBS with 1.8% NaCl, mounted on slides with Prolong Gold or Diamond mounting agents (Life Technologies; P36935 and P36961). cell morphology measurements (volume, surface area and skeletal length) were obtained using an intensitybased automated segmentation algorithm in Volocity ("find objects") followed by a fine filter. Homer1 and PSD95 puncta were identified using the "find spots" algorithm in Volocity software, which identifies puncta based on local intensity maxima that also exceed an intensity threshold value. For all measurements, values from image stacks in 6 tissue sections per mouse were averaged and expressed relative to sham-immunized controls from the same genotype and graphed as mean ± SEM. Experimenters were blinded to genotype or immunization group throughout each IHC experiment and subsequent data analysis.
Cued and Contextual Fear Conditioning:
Experiments were performed as previously reported (47) . Briefly, mice underwent fear conditioning at 25-28 days post immunization. Mice were placed in an isolation chamber with a metal grid floor and presented with a 15 second white noise cue co-terminating with an electric shock (2 seconds at 0.19 mA). Paired cue and shock were delivered 3 times, 30 s apart. Mice were then returned to their home cage overnight. Twenty four hours later, freezing behavior in response to the conditioned context, a novel context and the white noise cue was measured. To test the contextual conditioning responses, mice were placed in the same isolation chamber, prepared identically for conditioning, and video recorded for 5 minutes without stimulus for subsequent motion analysis (conditioned context test). After returning mice to their home cage for 3 hours, novel context and cued conditioning responses were tested by placing mice in a round test cage with smooth plastic walls wiped with ethanol, the floor covered with clean cage bedding, and illuminated with a red light to provide a novel context that differed from the conditioned context in shape, texture, odor and color. Video for motion analysis was recorded for 3 minutes without stimulus (novel context test) followed by 3 minutes of continuous presentation of the white noise cue (cue test). Freeze Frame / Freeze View, Actimetrics Software was used to analyze motion to detect episodes of freezing behavior which were defined as ≥ 0.5 s bouts of immobility except for the movements associated with breathing. Freezing responses were quantified as the percentage of total time spent freezing from 30-180 s after being placed in the conditioned or novel context, and the first 60 s of cue presentation (beyond which responses tended to deteriorate at variable rates). Because EAE mice had increased rates of immobility at baseline reflecting motor deficits, we subtracted rates of freezing during exposure to the novel, unconditioned context from rates during the conditioned context and cue tests to generate a measure (∆ freeze) that reflected increased freezing due to the mouse's ability to discriminate between the conditioned and novel context, and in response to the cue.
These values were normalized to those of the sham-immunized controls for the same testing cohort. Mice with >75 % immobility over the duration of the novel context were excluded from the ∆ freeze analysis, as high baseline immobility limited the measurement of conditioning effects. were conditioned with a foot shock and paired auditory cue, and bouts of freezing behavior were measured 24 hours later when mice were returned to the conditioned context, placed in a novel context, and presented with the cue. B) Group averages of percentage of time spent freezing, shown for 30-s epochs in each condition. Because EAE mice of both genotypes had reduced mobility and higher rates of non-specific freezing in a novel context, incremental increases in freezing in the conditioned vs. novel context (∆ context) and cue vs novel context (∆ cue) were used to measure changes in freezing behavior due to contextual and cued fear conditioning, respectively. C) Contextual fear conditioning was impaired in wild type EAE mice and little improved by C1qa knockout, while cued fear conditioning was not significantly affected by EAE or genotype. WT sham: n = 20; WT EAE: n = 19; C1qa KO sham: n = 24; C1qa KO EAE: n = 24. Statistical analysis: 2-Way ANOVAs with Sidak's multiple comparison tests. Error bars = SEM.
